Clin2Atlas
AtlasMental health & substance useSubstance use disorders

Alcohol use disorders

2Disease-modifyingAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251995 — Nalmefene approved (FDA)2004 — Acamprosate approved (FDA)
1995: Drug approval — Nalmefene approved (FDA). 2004: Drug approval — Acamprosate approved (FDA)

What's being tested now

2005: 1 trials started2013: 1 trials started2014: 5 trials started2015: 2 trials started2016: 1 trials started2017: 4 trials started2019: 9 trials started2020: 7 trials started2021: 15 trials started2022: 22 trials started2023: 33 trials started2024: 65 trials started2025: 84 trials started2026: 86 trials started20102020202686

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 321 active Alcohol Abuse trials on Clin2 →

Related

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.